阻塞性睡眠呼吸暂停对急性冠脉综合征预后的影响因肥胖状态而异
这项前瞻性队列研究连续纳入1920例18至85岁因急性冠脉综合征住院的患者,临床稳定后接受便携式睡眠监测,阻塞性睡眠呼吸暂停定义为呼吸暂停低通气指数≥15次/小时。中位随访2.9年,肥胖患者主要不良心脑血管事件发生率显著高于非肥胖患者(HR 1.29,95%CI 1.06-1.58,P=0.013)。阻塞性睡眠呼吸暂停仅在不肥胖患者中独立预测主要不良心脑血管事件(校正HR 1.34,95%CI 1.03-1.75,P=0.03),在肥胖患者中无此关联(校正HR 1.10,95%CI 0.78-1.55,P=0.58),肥胖与阻塞性睡眠呼吸暂停交互作用无统计学意义(交互P=0.35)。作者认为应重视在不肥胖急性冠脉综合征患者中识别阻塞性睡眠呼吸暂停。
要点
- 不肥胖急性冠脉综合征患者中,阻塞性睡眠呼吸暂停独立预测主要不良心脑血管事件(校正HR 1.34,95%CI 1.03-1.75,P=0.03)。
- 肥胖急性冠脉综合征患者中,阻塞性睡眠呼吸暂停与主要不良心脑血管事件无独立关联(校正HR 1.10,95%CI 0.78-1.55,P=0.58)。
- 肥胖患者主要不良心脑血管事件发生率显著高于非肥胖患者(HR 1.29,95%CI 1.06-1.58,P=0.013)。
- 非肥胖患者阻塞性睡眠呼吸暂停患病率低于肥胖患者(43.9% vs 67.5%,P<0.001)。
- 肥胖与阻塞性睡眠呼吸暂停对主要不良心脑血管事件的交互作用无统计学意义(交互P=0.35)。
适用人群与场景
- 18至85岁因急性冠脉综合征住院、临床稳定后接受便携式睡眠监测并连续纳入的前瞻性队列患者。
诊断标准与关键阈值
- 阻塞性睡眠呼吸暂停定义为呼吸暂停低通气指数≥15次/小时。
- 肥胖定义为BMI≥28 kg/m2。
研究设计与关键结果
- 前瞻性队列研究,纳入1920例患者(84.5%男性;平均年龄±标准差56.4±10.5岁),1013例(52.8%)有阻塞性睡眠呼吸暂停,718例(37.4%)肥胖。
- 主要终点为主要不良心脑血管事件,包括心血管死亡、因急性冠脉综合征住院、卒中、缺血驱动的血运重建或因心力衰竭住院。
- 随访2.9年(1.5,3.6年)期间,肥胖患者主要不良心脑血管事件发生率显著高于非肥胖患者(HR 1.29,95%CI 1.06-1.58,P=0.013)。
- 非肥胖患者阻塞性睡眠呼吸暂停患病率低于肥胖患者(43.9% vs 67.5%,P<0.001)。
- 阻塞性睡眠呼吸暂停仅在不肥胖患者中独立预测主要不良心脑血管事件(校正HR 1.34,95%CI 1.03-1.75,P=0.03),在肥胖患者中无独立关联(校正HR 1.10,95%CI 0.78-1.55,P=0.58)。
- 肥胖与阻塞性睡眠呼吸暂停的交互作用无统计学意义(交互P=0.35)。
- 不肥胖患者中阻塞性睡眠呼吸暂停相关的风险增加可能由更多因急性冠脉综合征住院和缺血驱动的血运重建解释。
证据类型、等级与局限
- 证据类型:前瞻性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,这些发现强调在不肥胖急性冠脉综合征患者中识别阻塞性睡眠呼吸暂停的重要性。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: A close relationship exists between OSA and obesity. The impact of obesity on the prognostic significance of OSA in patients with acute coronary syndrome (ACS) remains unclear.
RESEARCH QUESTION: Do the effects of OSA on subsequent cardiovascular events in patients with ACS vary with obesity status?
STUDY DESIGN AND METHODS: This is a prospective cohort study. Patients 18 to 85 years of age who were hospitalized for ACS were consecutively enrolled and underwent portable sleep monitoring after clinical stabilization. OSA was defined as an apnea hypopnea index ≥ 15 events/h. The primary end point was major adverse cardiovascular and cerebrovascular event (MACCE), including cardiovascular death, hospitalization for ACS, stroke, ischemia-driven revascularization, or hospitalization for heart failure.
RESULTS: Among 1,920 patients enrolled (84.5% male; mean age ± SD, 56.4 ± 10.5 years), 1,013 (52.8%) had OSA, and 718 (37.4%) were obese (BMI ≥ 28 kg/m2). During 2.9 years (1.5, 3.6 years) follow-up, the incidence of MACCE was significantly higher in patients with obesity than in patients without obesity (hazard ratio [HR], 1.29; 95% CI, 1.06-1.58; P = .013). Although the prevalence of OSA was lower in patients without obesity than in those with obesity (43.9% vs 67.5%; P < .001), OSA independently predicted the incidence of MACCE only in patients without obesity (adjusted HR, 1.34; 95% CI, 1.03-1.75; P = .03), but not in patients with obesity (adjusted HR, 1.10; 95% CI, 0.78-1.55; P = .58). No significant interaction between obesity and OSA was noted (P for interaction = .35). The incremental risk associated with OSA in patients without obesity might be explained by more hospitalization for ACS and ischemia-driven revascularization.
INTERPRETATION: For patients with ACS, OSA was independently associated with an increased risk of subsequent events, particularly among patients without obesity. These findings highlight the importance of identifying OSA in nonobese patients with ACS.
CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov; No.: NCT03362385; URL: www.
CLINICALTRIALS: gov.
参考来源
- Hao W, Wang X, Fan J, et al. Prognostic Implications of OSA in Acute Coronary Syndrome by Obesity Status. Chest. 2023. PMID: 36764513. doi:10.1016/j.chest.2023.02.001
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。